Intrathecal Ziconotide Antalgic Efficacy for Severe Refractory Neuropathic

Drug
Pain
Online since 2 January 2024, updated 196 days ago

About this trial

Spinal cord injury (SCI) has an average prevalence of 50 per 100.000 in general population (30.000 patients with SCI in France) with estimates of the overall prevalence for severe neuropathic pain ran...

Included participants

Gender
All
Age
≥ 18 years
Injury level
C1 - S5
  • Severity (AIS)?
  • AIS-A
    AIS-B
    AIS-C
    AIS-D
    Time since injury
    ≥ 0 hours
  • Injury type
  • Traumatic

    Healthy volunteers
    No
    C1-S5

    What’s involved

    Type

    Drug

    Details

    There are no details yet

    Potential benefits

    Main benefits

    Pain

    Additional benefits

    General health

    Mental health and psychosocial factors

    Good to know: Potential benefits are defined as outcomes that are being measured during and/or after the trial.

    Wings for Life supports SCITrialsFinder

    Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.

    Learn more

    • Trial recruitment status
    • Unknown
    • Trial start date
    • 20 Jun 2019
    • Organisation
    • Hospices Civils de Lyon
    • Trial recruitment status
    • Unknown
    • Trial start date
    • 20 Jun 2019
    • Organisation
    • Hospices Civils de Lyon

    Wings for Life supports SCITrialsFinder

    Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.

    Learn more